Free Trial
NASDAQ:GNVC

GenVec (GNVC) Stock Price, News & Analysis

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)
Free GNVC Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$7.19
▼
$7.19
50-Day Range
N/A
52-Week Range
$2.70
▼
$10.44
Volume
N/A
Average Volume
259,136 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
GNVC stock logo

About GenVec Stock (NASDAQ:GNVC)

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

GNVC Stock News Headlines

December 18, 2023 | dailymail.co.uk
Cold virus can hunt down cancer
November 7, 2023 | morningstar.com
Huangshan Novel Co Ltd Class A 002014
April 26, 2024 | Stansberry Research (Ad)
Move Your Money Before May 22
The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.
March 28, 2023 | finanznachrichten.de
MaxCyte, Inc: MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
February 20, 2023 | thestreet.com
GenVec Stock Hit by Pancreas Study's Details
January 3, 2023 | thestreet.com
Early Volume Plays: Novavax, GenVec
December 18, 2022 | thestreet.com
GenVec Value Slammed on Drug Failure
See More Headlines
Receive GNVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GenVec and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2016
Today
4/26/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:GNVC
CUSIP
N/A
CIK
934473
Web
www.genvec.com
Phone
+1-240-6320740
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Wayne T. Hockmeyer Ph.D.
    Independence Chairman of the Board
  • Douglas J. Swirsky
    President, Chief Executive Officer, Corporate Secretary, Director
  • William N. Kelley M.D.
    Independent Director
  • Stefan D. Loren Ph.D.
    Independent Director
  • Quinterol J. Mallette M.D.
    Independent Director
  • Michael S. Richman
    Independent Director
  • Marc R. Schneebaum
    Independent Director

GNVC Stock Analysis - Frequently Asked Questions

How were GenVec's earnings last quarter?

GenVec Inc (NASDAQ:GNVC) issued its quarterly earnings data on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.07 million.

When did GenVec's stock split?

GenVec shares reverse split before market open on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of GenVec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GenVec investors own include Sarepta Therapeutics (SRPT), Alibaba Group (BABA), NVE (NVEC), Microbot Medical (MBOT), Pluristem Therapeutics (PSTI), Acer Therapeutics (ACER), Chesapeake Energy (CHKAQ), MicroVision (MVIS) and Stone Energy (SGY).

This page (NASDAQ:GNVC) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
These AI trades triggered this morning (545% return)
Prosper Trading Academy
Exposed: 10 CENT Crypto to Explode April 20th?
True Market Insiders
He Is Giving Away Bitcoin
Crypto Swap Profits
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research
Biden out June 13; Kamala won’t replace him?
Paradigm Press